Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

23.52 +0.52 (+2.26%)
Official Closing Price Updated: 7:00 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stay informed about the most active stocks in the S&P500 index on Tuesday's session.
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention. 
Via Chartmill
P/E Ratio Insights for Pfizer
Via Benzinga
Pfizer Stock Is Trading Higher Tuesday: What's Going On?
Pfizer Inc (NYSE:PFE) shares are moving higher Tuesday following multiple developments. Here's a look at what's going on. 
Via Benzinga
FDA Sets New Guidelines For Approving COVID-19 Booster Shots In Healthy Individuals: Moderna, Novavax Stocks Rise
The agency plans to demand stronger evidence of efficacy for the shots before approval is granted for healthy persons, between the ages of six months and 64 years, with no risk factors for severe... 
Via Stocktwits
Exposures COVID-19 Product Safety
The FDA Is Limiting Covid Shots. But Moderna, Vaccine Stocks Jumped.
The new framework limits future Covid shots to people age 65 and older and those six months and older with a risk factor for serious illness. 
Via Investor's Business Daily
Topics Bankruptcy Government
Exposures COVID-19 Financial Legal
How Do Investors Really Feel About Pfizer?
Via Benzinga
WeRide Teams Up With Tencent Cloud To Accelerate Global Robotaxi Ambitions
The company said Tencent Cloud will allow it to offer localized and compliant cloud services in countries outside of China, accelerating the commercial rollout of its robotaxi services overseas. 
Via Stocktwits
Topics Supply Chain
Exposures Supply Chain
Pfizer Strikes Deal With China’s 3SBio For Experimental Cancer Drug License
3SBio’s experimental cancer drug is currently undergoing clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors. 
Via Stocktwits
Topics Government
Exposures Political
Sell-Off Grips Dalal Street: Nifty Ends Below 24,700; Metals Shine On China Rate Cut
Indian markets ended sharply lower, dragged by broad-based profit booking, FPI outflows, and fading optimism over the U.S.-India trade deal. 
Via Stocktwits
Topics Economy
Exposures Coal Economy Interest Rates
These 3 Dividend Stocks Yield More Than 6% and Their Payouts Look Safe
Via The Motley Fool
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Pfizer Secures Global Rights To China's 3SBio's Cancer Drug In $6 Billion Deal
Pfizer Inc. announced Monday it has secured exclusive global rights, excluding China, to 3SBio Inc.'s bispecific antibody SSGJ-707. 
Via Benzinga
Retail Bulls Cheer FDA Clearance For BrainStorm’s ALS Therapy, But Shares Dip After Hours
BrainStorm Cell Therapeutics plans to enroll 200 ALS patients in its FDA-cleared Phase 3b trial of NurOwn, with a 24-week double-blind phase followed by an open-label extension. 
Via Stocktwits
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Novavax Scores Key FDA Win, Shares Jump 19% As Sanofi Unlocks Milestone Payment
Novavax's COVID-19 vaccine, Nuvaxovid™, receives limited FDA approval and triggers $175M milestone payment. Commercial distribution planned for fall. 
Via Benzinga
Exposures COVID-19 Product Safety
Novavax Wins Limited FDA Nod For COVID Shot—Cleared Only For Seniors, High-Risk Groups Amid Safety Scrutiny
The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.'s COVID-19 vaccine, restricting its use to people 65 and older and those 12 and up with underlying health conditions... 
Via Benzinga
Exposures COVID-19 Product Safety
India Market Watch: Muted Start For Nifty, Sensex — Defense Stocks, Delhivery Shine
Via Stocktwits
1 Profitable Stock on Our Watchlist and 2 to Turn Down
A company with profits isn’t always a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
Novavax Wins FDA Approval For COVID-19 Vaccine: Retail Calls For Buyback And Bigger Moves
The pharma company secured FDA clearance to manufacture and distribute its COVID-19 vaccine Nuvaxovid for adults and at-risk groups, with no advisory committee hurdles. 
Via Stocktwits
Exposures COVID-19 Product Safety
Don't Fall for These 3 Dividend Stocks: They May Have to Make a Cut.
Here are three dividend-paying stocks that warrant closer examination. 
Via The Motley Fool
Exposures COVID-19
Here's How Many Shares of Pfizer You Should Own to Make $10,000 in Annual Dividend Income
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
3 Profitable Stocks to Research Further
Profitability is a key measure of business strength. Companies with high margins have proven they can generate consistent earnings while maintaining financial discipline. 
Via StockStory
Why Pfizer Is Poised For A Strong Comeback: My Top Pick For 2025
For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity. 
Via Benzinga
What Most-Favored-Nation Status Could Mean for Pharmaceutical Stocks
Via The Motley Fool
Topics Economy Government
Exposures Interest Rates Political
3 Magnificent S&P 500 Dividend Stocks Down 62%, 63%, and 64% to Buy and Hold Forever
Temporary turbulence has resulted in opportunity for patient, bargain-hunting investors. 
Via The Motley Fool
Topics Economy Stocks World Trade
Exposures Economy Tariff US Equities
Curious about the most active S&P500 stocks in today's session?
Looking for the most active stocks in the S&P500 index on Wednesday? Dive into today's session and discover the stocks that are dominating the trading activity and setting the pace for the market. 
Via Chartmill
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030
Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states. 
Via Benzinga
3 Value Stocks Facing Headwinds
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
Jim Cramer Is 'OK' With Harrow, Recommends Buying This Energy Stock
Jim Cramer takes a look at Harrow, Pfizer, Kinsale Capital, Manulife Financial, Iron Mountain and more on "Mad Money." 
Via Benzinga
PFE Q1 Earnings Call: Revenue Misses, Margin Expansion, and Focus on Pipeline Productivity
Global pharmaceutical company Pfizer (NYSE:PFE) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 7.8% year on year to $13.72 billion. The company’s full-year revenue guidance... 
Via StockStory
Topics World Trade
Exposures Tariff
Market Monitor News May 12 ( NRG Energy, Amazon, Meta Platforms UP - CVS Health DOWN)
Wall Street surges sharply as US-China tariff cuts drive tech stocks higher; pharma sector gains on new Trump drug pricing initiative. 
Via Chartmill
Topics Government World Trade
Exposures Political Tariff
Which S&P500 stocks are the most active on Monday?
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.